Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R21 + AS01B (University of Oxford, 0440a5)
- Development stage
- Unknown
- Lead developer
- University of Oxford
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
R21 + AS01B is an experimental malaria vaccine candidate consisting of the R21 virus-like particle (VLP) antigen and the AS01B adjuvant system. R21 is a recombinant protein particle that displays the circumsporozoite protein (CSP) of *Plasmodium falciparum*, designed to elicit high-titer antibodies and T-cell responses against the pre-erythrocytic stage of the malaria parasite. AS01B is a liposome-based adjuvant system developed by GSK, containing two immunostimulants: MPL (3-O-desacyl-4'-monophosphoryl lipid A) and QS-21. This specific formulation was evaluated in a Phase I clinical trial (NCT02600975) by the University of Oxford's Jenner Institute to assess safety and immunogenicity in healthy adults. While R21 was initially tested with AS01B, the program ultimately transitioned to using the Matrix-M adjuvant for later-stage development and eventual regulatory approval.
- Other names
- R21/AS01B
02
Targets
TLR4 (Toll-like receptor 4)CSP (Circumsporozoite protein)
Beyond the preview
Go deeper on R21 + AS01B (University of Oxford, 0440a5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R21 + AS01B (University of Oxford, 0440a5).